News

The Latvian Medicines Verification Organization (LZVO) is launching The Newsletter No. 6, where you can find the most important information about events in the world of medicines verification in the second quarter of 2023.

There have been team changes in the Latvian Medicines Verification Organization (LZVO). Since July 17, 2023, Sanda Čerdinceva has taken on the role of the new Quality Manager.

In the 2nd quarter of 2023, 27 million transactions have been performed in the Latvian Medicines Verification System (LZVS), of which 7 million packages were decommissioned and supplied to patients.

To ensure that the Latvian Medicines Verification Organisation’s (LZVO) newsletters meet the needs of end users in terms of content and format, LZVO conducted a survey of end users in May of this year. Among those respondents (242 end users) who assessed the relevance and value of the newsletters’ information, 76% or 185 respondents rated the relevance and value of information as very good or good.

The Latvian Medicines Verification Organisation (LZVO), aiming to improve the quality of work and collaboration, conducted an end user survey on LZVO's customer service in May of this year. LZVO's customer service received a high evaluation in the survey – LZVO's customer service was rated with 4.3 points overall (on a 5-point system).

The European Medicines Verification Organisation (EMVO) has launched a newsletter, which informs about the statement from EMVO’s new President, the roles and responsibilities of the National Medicines Verification Organisations (NMVO) Observers, the experience from the Hungarian Medicines Verification Organisation in ending the stabilisation period, the Belgium's experience with the Nordic recommendations on the recalls of batches and withdrawal of products, as well as on the status of alerts in the European Medicines Verification System (EMVS).